Genomic manipulation provides a powerful opportunity to understand how iPSCs derived from patients with known amyloid mutations, especially TTR-ACM, can help study amyloid disease phenotypes in an isogenic background [84,85,86] (Figure 2). The gene discussed is TTR; the disease is amyloidosis.